News

Bayer CropScience signs R&D pact
Enlarge image

ResearchGermany

Bayer CropScience signs R&D pact

06.09.2012 - Bayer CropScience and US firm Mendel Biotechnology will co-develop a herbicide resistance breaking technology.

The focus of the new multi-year collaboration with the US plant genomics specialist is to jointly identify herbicides with novel modes of action, because many weeds have developed resistance to multiple herbicide classes. Under the terms of the agreement, the global No. 2 in herbicides, will bring in its expertise in herbicide research and development. Mendel will contribute its knowledge of plant genetic regulatory networks (PGRNs) – especially its know-how on regulatory transcription factors that can contribute to herbicide resistance. 
  

“We believe that this collaboration will help us continue our significant contributions in agricultural chemistry“, quoted Dr. C. David Nicholson, Global Head of Research & Development at Bayer CropScience. He added he hoped the combined know-how would  help growers to tackle weed resistance issues and to protect their crops.”



Mendel has already partnered with the Germans in identifying chemicals that modulate the plant’s stress response signalling networks. The company has extensive knowledge on the set of transcription factors and regulatory networks in different plants identified by 1st PGRN platform and hold patents on cold and drought resistance

http://www.european-biotechnology-news.com/news/news/2012-03/bayer-cropscience-signs-rd-partnership.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SCANCELL HOLDINGS (UK)29.25 GBP7.93%
  • CELLECTIS (F)32.30 EUR7.31%
  • ALMIRALL (E)17.87 EUR7.26%

FLOP

  • TRANSGENE (F)3.99 EUR-14.56%
  • BAVARIAN NORDIC (D)39.72 EUR-5.61%
  • EUROFINS SCIENTIFIC (F)255.00 EUR-5.39%

TOP

  • PROTHENA PLC (IE)52.67 USD31.8%
  • VERONA PHARMA (UK)5.20 GBP22.4%
  • DBV Technologies (F)51.87 EUR21.8%

FLOP

  • OREXO (S)68.00 SEK-24.7%
  • NORDIC NANOVECTOR (N)26.90 NOK-23.6%
  • SCANCELL HOLDINGS (UK)29.25 GBP-23.5%

TOP

  • ADOCIA (F)67.19 EUR387.9%
  • 4SC (D)4.52 EUR352.0%
  • WILEX (D)3.64 EUR343.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.60 SEK-70.3%
  • NEOVACS (F)1.12 EUR-67.0%

No liability assumed, Date: 30.06.2015